Promoted Content

Promoted Content

X

[{"orgOrder":0,"company":"Inipharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"Undisclosed","newsHeadline":"Inipharm Raises $35 Million in Series A to Focus on Highly Validated Genetic Target HSD17B13","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Inipharm"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"Temasek Life Sciences Laboratory","pharmaFlowCategory":"D","amount":"$215.0 million","upfrontCash":"Undisclosed","newsHeadline":"Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Arbor Biotechnologies, Inc"},{"orgOrder":0,"company":"Aligos Therapeutics","sponsor":"Merck & Co. Inc.","pharmaFlowCategory":"D","amount":"$1,380.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Aligos Therapeutics"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Novartis Announces Collaboration with Alnylam to Explore Targeted Therapy to Restore Liver Function","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","amount":"$466.0 million","upfrontCash":"$60.0 million","newsHeadline":"Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Verve Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Verve Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease

Details:

Under the terms of the collaboration, Verve will advance the discovery, research and certain preclinical development of a novel in vivo gene editing program for the target of interest, with all program costs funded by Vertex.

Lead Product(s): In-vivo Gene Editing Medicines

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Vertex Pharmaceuticals

Deal Size: $466.0 million Upfront Cash: $60.0 million

Deal Type: Collaboration July 20, 2022

ASK
US

Upload
your Pipeline Activity

Aligos Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Aligos Therapeutics Expands Collaboration with Merck to Develop Oligonucleotide Therapies for NASH

Details:

Under the original agreement, Merck and Aligos committed to applying Aligos’ oligonucleotide platform technology to discover, research, optimize and develop oligonucleotides directed against a certain undisclosed non-alcoholic steatohepatitis (NASH) target.

Lead Product(s): Oligonucleotide Therapy

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: $1,380.0 million Upfront Cash: Undisclosed

Deal Type: Expanded Collaboration January 11, 2022

ASK
US

Upload
your Pipeline Activity

Alnylam Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novartis Announces Collaboration with Alnylam to Explore Targeted Therapy to Restore Liver Function

Details:

Novartis and Alnylam have agreed to collaborate on discovery and development of siRNA-based targeted therapy to restore functional liver cells in patients with end-stage liver disease.

Lead Product(s): siRNA-based Targeted Therapy

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 06, 2022

ASK
US

Upload
your Pipeline Activity

Arbor Biotechnologies, Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Arbor Biotechnologies Closes $215 Million Oversubscribed Series B Financing to Advance Next-Generation Precision Editing Therapeutics

Details:

Arbor plans to use the proceeds to advance its lead programs in liver and CNS disease into the clinic and progress a pipeline of precision editing therapeutics, while continuing to invest in its novel discovery engine to develop the next generation of gene editing technology.

Lead Product(s): Nuclease Therapies

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Temasek Life Sciences Laboratory

Deal Size: $215.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing November 09, 2021

ASK
US

Upload
your Pipeline Activity

Inipharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Inipharm Raises $35 Million in Series A to Focus on Highly Validated Genetic Target HSD17B13

Details:

Inipharm will use the Series A funding to push the lead program — which targets the HSD17B13 gene —through IND filing and into the clinic.

Lead Product(s): Undisclosed

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $35.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing November 11, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY